Welcome to our dedicated page for Cidara Theraptcs news (Ticker: CDTX), a resource for investors and traders seeking the latest updates and insights on Cidara Theraptcs stock.
Cidara Therapeutics, Inc. (CDTX) generates news primarily as a clinical-stage biotechnology company developing drug-Fc conjugate (DFC) therapeutics through its proprietary Cloudbreak platform. Most recent coverage focuses on CD388, a long-acting antiviral DFC designed as a non-vaccine preventative for seasonal and pandemic influenza, as well as on corporate transactions and government collaborations.
News about Cidara frequently highlights clinical trial milestones for CD388. This includes updates on the Phase 2b NAVIGATE trial in healthy unvaccinated adults and the Phase 3 ANCHOR trial in adults and adolescents at higher risk of influenza complications, including individuals with immune-compromised conditions, certain comorbidities, and adults over 65 years of age. Articles often describe trial design, enrollment progress, interim analysis plans, and safety and efficacy results reported by the company.
Investors following CDTX news will also see disclosures on regulatory interactions and designations, such as Fast Track and Breakthrough Therapy designations granted by the U.S. Food and Drug Administration (FDA) for CD388, and company commentary on plans to seek biologics license application (BLA) approval based on a single Phase 3 study. Additional coverage includes Cidara’s BARDA agreement to support expanded manufacturing and clinical development of CD388, detailing federal funding for onshoring manufacturing and additional clinical and non-clinical work.
Another major theme in Cidara’s news flow is its acquisition by Merck. Releases describe Merck’s definitive agreement to acquire Cidara through a cash tender offer and subsequent merger, the tender offer terms, and Merck’s statements about integrating CD388 into its respiratory portfolio. Updates from Merck note the successful completion of the tender offer, the planned merger to make Cidara a wholly owned subsidiary, and the expected delisting of Cidara’s common stock from the Nasdaq Global Market.
On this CDTX news page, readers can review historical and transaction-related announcements, clinical data presentations at scientific conferences, investor conference participation, and quarterly corporate updates. For those researching Cidara’s development of CD388, its Cloudbreak platform, and the transition of Cidara into Merck’s portfolio, this news feed provides a centralized view of key public communications over time.
Cidara Therapeutics (Nasdaq: CDTX), a biotechnology company focused on drug-Fc conjugate therapeutics through its Cloudbreak® platform, has announced its inclusion in both the Russell 2000® and Russell 3000® Indexes. The Russell 3000 Index represents the 3,000 largest U.S. companies by market cap, covering approximately 98% of the investable U.S. equity market, while the Russell 2000 Index focuses on the small-cap segment.
CEO Jeffrey Stein highlighted this milestone alongside other recent company achievements, including positive Phase 2b NAVIGATE trial results and a successful $400 million financing round. The index inclusion is expected to increase Cidara's visibility among institutional investors.
Cidara Therapeutics (Nasdaq: CDTX), a biotechnology company, has successfully completed an upsized public offering of 9,147,727 shares of common stock at $44.00 per share. The offering includes the full exercise of underwriters' option to purchase an additional 1,193,181 shares. The company raised gross proceeds of $402.5 million before deducting underwriting discounts and commissions.
The offering was managed by prominent financial institutions including J.P. Morgan, Morgan Stanley, Guggenheim Securities, and Cantor as joint book-running managers. The shares were offered through a shelf registration statement on Form S-3 that was declared effective by the SEC on May 15, 2025.
Cidara Therapeutics (Nasdaq: CDTX), a biotechnology company specializing in drug-Fc conjugate therapeutics through its Cloudbreak® platform, has announced the pricing of an upsized public offering. The company will offer 7,954,546 shares at $44.00 per share, expecting to raise $350.0 million in gross proceeds before deductions.
The offering includes a 30-day option for underwriters to purchase up to 1,193,181 additional shares at the public offering price. The offering, expected to close on June 26, 2025, is being managed by J.P. Morgan, Morgan Stanley, Guggenheim Securities, and Cantor as joint book-running managers.
Cidara Therapeutics (Nasdaq: CDTX), a biotechnology company specializing in drug-Fc conjugate therapeutics through its Cloudbreak® platform, has announced plans for a $250.0 million underwritten public offering of common stock. The company intends to grant underwriters a 30-day option to purchase up to an additional 15% of shares.
The offering will be managed by joint book-runners J.P. Morgan, Morgan Stanley, Guggenheim Securities, and Cantor. The offering is being made through a shelf registration statement on Form S-3 that was declared effective by the SEC on May 15, 2025.
Cidara Therapeutics (NASDAQ: CDTX) announced it will host a virtual R&D day on May 22, 2025, from 10:00 to 11:30 AM ET to discuss CD388, their innovative long-acting antiviral drug designed for universal, once-per-flu season prevention of seasonal and pandemic influenza.
The event will feature key opinion leaders Dr. Fred Hayden from the University of Virginia School of Medicine and Dr. Rick Bright from the Pandemic Prevention Institute. Topics will include the 2024-2025 flu season review, updates on the ongoing Phase 2b NAVIGATE trial's statistical analysis plan, planned Phase 3 study design, commercial opportunities, and competitive landscape for CD388.
Cidara Therapeutics (NASDAQ: CDTX), a biotechnology company specializing in drug-Fc conjugate therapeutics through its Cloudbreak® platform, has announced its participation in two upcoming investor conferences. The company will present at the RBC Global Healthcare Conference on May 21, 2025, at 10:00 AM ET, and the Jefferies Global Healthcare Conference on June 4, 2025, at 11:40 AM ET.
Both presentations will be available via live webcast through Cidara's investor relations website, with replays accessible for at least 30 days. The company will also engage in one-on-one meetings with investors during these events.
Cidara Therapeutics (CDTX) provided its Q1 2025 financial results and corporate updates. The company reached a key milestone with the data cutoff for its Phase 2b NAVIGATE trial on April 30, 2025, involving 5,041 subjects testing CD388 for influenza prevention. Top-line results are expected in late June 2025.
Key financial highlights include: cash position of $174.5M as of March 31, 2025, down from $196.2M in December 2024. Q1 2025 saw increased R&D expenses of $24.6M (vs $5.9M in Q1 2024) and a net loss of $23.5M (vs $10.3M in Q1 2024).
The company published preclinical data in Nature Microbiology highlighting CD388's potential as a universal antiviral for influenza prevention. Additionally, Cidara promoted Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to Senior Vice President of Clinical Development.
Cidara Therapeutics (Nasdaq: CDTX), a biotech company specializing in drug-Fc conjugate therapeutics through their proprietary Cloudbreak® platform, has announced their upcoming participation in The Citizens Life Sciences Conference.
The event details include:
- Conference: The Citizens Life Sciences Conference
- Date: Wednesday, May 7, 2025
- Time: 11:00 AM ET
- Format: Presentation
The presentation will be accessible via webcast, and a replay will be available in the Investors section of Cidara's website for at least 30 days. The company will also engage in one-on-one investor meetings during the event.